echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CANCER RES: Abnormal regulation of NEIL3 is associated with poor prognosis of liver cancer

    CANCER RES: Abnormal regulation of NEIL3 is associated with poor prognosis of liver cancer

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the third leading cause of cancer-related deaths worldwide


    Recently, a research team published an article on the overexpression of endonuclease viii-like protein 3 (NEIL3) in HCC, suggesting that the low survival rate of hepatocellular carcinoma (HCC) patients may be related to NEIL3


    The research team collected the tumor and non-tumor tissues of 202 patients with primary liver cancer who underwent hepatectomy from 2010 to 2015, randomly selected 80 pairs of tumors and matched non-tumor specimens, and used immunohistochemical staining to detect NEIL3 expression levels


    The results of the study indicate that the abnormal regulation of NEIL3 is associated with poor prognosis of liver cancer.


    NEIL3 mRNA overexpression is associated with decreased overall survival and progression-free survival

    Compared with non-tumor tissues, NEIL3 mRNA is overexpressed in HCC

    In short, the research team believes that NEIL3 is an independent prognostic marker and a new molecular target in the proliferation and progression of HCC


    When developing NEIL3 inhibitors, this may be important from a therapeutic point of view.


    Original source: Zhao Z, Gad H, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.